Baloxavir
Baloxavir Uses, Dosage, Side Effects, Food Interaction and all others data.
Baloxavir is under investigation in clinical trial NCT04327791 (Combination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)).
Trade Name | Baloxavir |
Availability | Prescription only |
Generic | Baloxavir |
Baloxavir Other Names | Baloxavir |
Related Drugs | amantadine, Tamiflu, oseltamivir, Fluzone, Vicks DayQuil Severe Cold & Flu, Xofluza, Coricidin HBP Cold & Flu, Afluria, Fluad |
Type | |
Formula | C24H19F2N3O4S |
Weight | Average: 483.49 Monoisotopic: 483.106433604 |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Food Interaction
[Moderate] GENERALLY AVOID: Coadministration with foods or medications that contain polyvalent cations such as dairy products, calcium-fortified beverages, certain laxatives, antacids, or oral supplements may decrease the plasma concentrations and therapeutic efficacy of baloxavir.
The proposed mechanism is chelation of baloxavir by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.
A significant decrease in baloxavir exposure was observed in monkeys when the prodrug, baloxavir marboxil, was coadministered with calcium, aluminum, magnesium, or iron.
However, clinical data in humans are lacking.
When baloxavir marboxil was administered with food, baloxavir peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 48% and 36%, respectively, relative to administration under fasting.
These changes are not considered clinically significant.
MANAGEMENT: Baloxavir marboxil may be taken with or without food.
However, coadministration with dairy products, calcium-fortified beverages, or polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc) should be avoided.
Baloxavir multivitamins interaction
[Moderate] GENERALLY AVOID: Coadministration with polyvalent cation-containing products may decrease the plasma concentrations and therapeutic efficacy of baloxavir.
The proposed mechanism is chelation of baloxavir by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.
A significant decrease in baloxavir exposure was observed in monkeys when the prodrug, baloxavir marboxil, was coadministered with calcium, aluminum, magnesium, or iron.
However, clinical data in humans are lacking.
Concurrent administration of baloxavir marboxil with polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., aluminum, calcium, iron, magnesium, selenium, zinc) should generally be avoided.
Innovators Monograph
You find simplified version here Baloxavir